Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of…
Amneal Pharmaceuticals, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of…
Read More...
Read More...
